A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

Capecitabine, a prodrug of 5-FU, has been reported to generate maximal tumour activity at tumour sites and/or to improve drug tolerability as compared with 5-FU infusion, and it has also been demonstrated to act synergistically with irinotecan against some solid cancers. A previous study concluded t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Oh, S C, Sur, H Y, Sung, H J, Choi, I K, Park, S S, Seo, J H, Jeen, Y T, Chun, H J, Shin, S W, Mok, Y J, Kim, J S, Kim, Y H
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2007
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2359951/
https://ncbi.nlm.nih.gov/pubmed/17473829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603752
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi